Marianne De Backer, Vir Biotechnology CEO (Brian Benton Photography)
January 8, 2025 07:45 AM ESTUpdated 05:16 PM
R&D

Vir’s ear­ly T cell en­gager da­ta of­fer first look at can­cer piv­ot, stock jumps

Elizabeth Cairns

Senior biopharma journalist

In­ter­im da­ta on two T cell en­gagers that Vir Biotech­nol­o­gy li­censed from Sanofi last year have be­gun to jus­ti­fy the biotech’s strate­gic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Coave rais­es €32M Se­ries A de­spite be­ing two years away from the clin­ic

Af­ter lack­lus­ter 2024, bio­phar­ma in­dus­try prays stalled M&A will fi­nal­ly move in­to gear

Astel­las stops de­vel­op­ing au­tol­o­gous cell ther­a­py us­ing tech from Xyphos buy­out

A service from the Financial Times